Valuation
- Market cap
- 11,081,000
- Revenue TTM
- $0
- Net income TTM
- $-7,980,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 47,300
- Avg volume
- 50,642
- Day's range
- $3.92 – $4.28
- Shares out
- 2,626,000
- Stochastic %K
- 65%
- Beta
- 1.50
- Analysts
- Sell
- Price target
- $9.50
Company profile
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and oth...
Show more
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 804 487 8196
- Website
- https://www.adial.com
- Address
- 4870 Sadler Road, Suite 300, Glen Allen, United States
Latest news
No headlines yet.
